Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20190654 | 0.86 | FFAR1 (0.38) | KAT6AFFAR1 | |
| Hydrochloric Acid SCHEMBL20190655 | 0.86 | FFAR1 (0.38) | KAT6AFFAR1 | |
| SCHEMBL18374081 | 0.85 | KAT6A (0.39) | KAT6AFFAR1ACACBACACA | |
| SCHEMBL20376634 | 0.85 | KAT6A (0.39) | KAT6AFFAR1ACACBACACA | |
| SCHEMBL12077349 | 0.82 | KAT6A (0.46) | KAT6A | |
| SCHEMBL20201680 | 0.81 | KDM1A (0.40) | ACACBACACA | |
| SCHEMBL21610851 | 0.80 | FFAR1 (0.41) | FFAR1FFAR4ACACB | |
| SCHEMBL20351738 | 0.79 | KAT6A (0.42) | KAT6AACACBACACA | |
| SCHEMBL24180197 | 0.78 | KAT6A (0.38) | KAT6AFFAR4ACACB | |
| SCHEMBL18374006 | 0.78 | KAT6A (0.44) | KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829457-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-11-10 | — | — | US | disclosed |
| US-10570098-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-25 | — | — | US | disclosed |
| US-20190276410-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829457-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | KAT6A 2222/4885FFAR1 4454/4885FFAR4 4661/4885 |
| US-10570098-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | KAT6A 1511/4885FFAR1 4576/4885FFAR4 4718/4885 |
| US-20190276410-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, DPYD, TYMP | KAT6A 2222/4885FFAR1 4454/4885FFAR4 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.